Tiago Costa

Dr. Tiago Costa

Pharmacology Department, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo 14049-900, Brazil
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in Vascular Pharmacology
Verified
Journal Article
Closed access
Tiago CostaTiago Costa
Tiago Costa
SPSimone R. Potje
Simone R. Potje
TFThais F.C. Fraga-Silva
Thais F.C. Fraga-Silva
JSJúlio A. da Silva-Neto
Júlio A. da Silva-Neto
PBPaula R. Barros
Paula R. Barros
RTRita de Cássia Tostes
Rita de Cássia Tostes

1 January 2021 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
Tiago CostaTiago Costa
Tiago Costa
PBPaula Rodrigues Barros
Paula Rodrigues Barros
CACristina Arce
Cristina Arce
JSJeimison Duarte Santos
Jeimison Duarte Santos
JSJúlio da Silva-Neto
Júlio da Silva-Neto
Francesc Jiménez-AltayóFrancesc Jiménez-Altayó
Francesc Jiménez-Altayó

25 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ACAna Mompeon Campos
Ana Mompeon Campos
LOLuis Ortega-Paz
Luis Ortega-Paz
XVXavier Vidal-Gomez
Xavier Vidal-Gomez
Tiago CostaTiago Costa
Tiago Costa
DPDaniel Pérez-Cremades
Daniel Pérez-Cremades
CHCARLOS HERMENEGILDO
CARLOS HERMENEGILDO
Despite the promising value of miRNAs in the diagnostic and prognostic of cardiovascular disease (CVD), recent meta-analyses did not support their potential. Methodological variances in studies may interfere with miRNA profile and affect their results. This study determines if the blood starting material is a source of variance in miRNA profile by performing a paired comparison in plasma and serum of the expression of primary miRNAs associated with CVD. Circulating miRNA yield was similar in both plasma and serum, although a significant increase was observed in patients with Non-ST-elevation myocardial infarction (NSTEMI) compared to control volunteers. When normalized by the expression of miR-484, different patterns of miRNA expression between serum and plasma. Although NSTEMI modified the expression of miR-1 and miR-208 in both serum and plasma, plasma displayed a higher variance than serum (Levene’s test p < 0.01). For miR-133a and miR-26a, differences were only detected in serum (p = 0.0240), and conversely, miR-499a showed differences only in plasma of NSTEMI (p = 0.001). Interestingly, miR-21 showed an opposite pattern of expression, being increased in serum (2−ΔΔCt: 5.7, p = 0.0221) and decreased in plasma (2−ΔΔCt: 0.5, p = 0.0107). Plasma and serum exhibit different patterns of circulating miRNA expression in NSTEMI and suggest that results from studies with different starting material could not be comparable.

1 February 2015 in Life Sciences
Verified
Journal Article
Closed access
Gisele F BomfimGisele F Bomfim
Gisele F Bomfim
CEC. Echem
C. Echem
CMC.B. Martins
C.B. Martins
Tiago CostaTiago Costa
Tiago Costa
SSS.M. Sartoretto
S.M. Sartoretto
MCM.H.C. Carvalho
M.H.C. Carvalho

1 July 2021 in Life Sciences
Verified
Journal Article
Closed access
SPSimone R. Potje
Simone R. Potje
Tiago CostaTiago Costa
Tiago Costa
TFThais F.C. Fraga-Silva
Thais F.C. Fraga-Silva
RMRonaldo B. Martins
Ronaldo B. Martins
MBMaira N. Benatti
Maira N. Benatti
RTRita de Cássia Tostes
Rita de Cássia Tostes

1 April 2015 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
Tiago CostaTiago Costa
Tiago Costa
Graziela S CeravoloGraziela S Ceravolo
Graziela S Ceravolo
Robson SantosRobson Santos
Robson Santos
MOMaria Aparecida de Oliveira
Maria Aparecida de Oliveira
PAPriscila X. Araújo
Priscila X. Araújo
MCMaria Helena C. Carvalho
Maria Helena C. Carvalho
Testosterone has been added to hormone replacement therapy to treat sexual dysfunction in postmenopausal women. Whereas estrogen has been associated with vascular protection, the vascular effects of testosterone are contradictory and the effects of its association with estrogen are largely unknown. In this study we determined the effects of testosterone associated with conjugated equine estrogen (CEE) on vascular function using a model of hypertensive postmenopausal female: ovariectomized spontaneously hypertensive rats. Female spontaneously hypertensive rats were divided into sham-operated, ovariectomized (OVX), and OVX treated for 15 days with either CEE alone (OVX+CEE) or associated with testosterone (OVX+CEE+T). Angiotensin II (ANG II)-induced contraction was markedly increased in aortic rings from OVX compared with sham-operated rats. CEE treatment restored ANG-II responses, a beneficial effect abrogated with CEE+T. CEE treatment also increased endothelium-dependent relaxation, which was impaired in OVX rats. This effect was lost by CEE+T. Treatment of aortas with losartan (ANG-II type-1 receptor antagonist) or apocynin (NADPH-oxidase inhibitor) restored the endothelium-dependent relaxation in OVX and CEE+T, establishing an interplay between ANG-II and endothelial dysfunction in OVX and CEE+T. The benefits by CEE were associated with downregulation of NADPH-oxidase subunits mRNA expression and decreased reactive oxygen species generation. The association of testosterone with CEE impairs the benefits of estrogen on OVX-associated endothelial dysfunction and reactive oxygen species generation in rat aorta by a mechanism that involves phosphorylation of the cytosolic NADPH-oxidase subunit p47 phox.